Serotonin regulates osteoclast differentiation through its transporter

Journal of Bone and Mineral Research

Volumn 19, Issue 9, 2004, Pages 1420-1431

  Battaglino, Ricardo ^a   Fu, Jia ^a   Späte, Ulrike ^a   Ersoy, Ulku ^a   Joe, Martha ^a   Sedaghat, Leela ^a   Stashenko, Philip ^a  

^a FORSYTH INSTITUTE   (United States)

Author keywords

Bone; Differentiation; Neural regulation; Osteoclasts; Serotonin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIDEPRESSANT AGENT; CELL MARKER; FLUOXETINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RESERPINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; CARRIER PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; NERVE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT PROTEIN; SEROTONIN RECEPTOR; SLC6A4 PROTEIN, MOUSE; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BIOLOGICAL MODEL; BONE DEVELOPMENT; BONE MARROW; BONE MASS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CYTOPLASM VESICLE; DNA MICROARRAY; DRUG CLEARANCE; HOMEOSTASIS; INTRACELLULAR TRANSPORT; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; STEM CELL; SYNAPSE; ANIMAL; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; NERVE TISSUE PROTEINS; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; RESERPINE; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 12344334748     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040606     Document Type: Article

References (65)

1. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC 1998 The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 273:34120-34127.
2. Hayashi S, Yamane T, Miyamoto A, Hemmi H, Tagaya H, Tanio Y, Kanda H, Yamazaki H, Kunisada T 1998 Commitment and differentiation of stem cells to the osteoclast lineage. Biochem Cell Biol 76:911-922.
3. Owens JM, Matsuo K, Nicholson GC, Wagner EF, Chambers TJ 1999 Fra-1 potentiates osteoclastic differentiation in osteoclast-macrophage precursor cell lines. J Cell Physiol 179:170-178.
4. Suda T, Jimi E, Nakamura I, Takahashi N 1997 Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol 282:223-235.
5. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
6. Takahashi N, Udagawa N, Suda T 1999 A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449-455.
7. Takeshita S, Kaji K, Kudo A 2000 Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15:1477-1488.
8. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T 1999 Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 25:517-523.
9. Abdouh M, Stoning JM, Riad M, Paquette Y, Albert PR, Drobetsky E, Kouassi E 2001 Transcriptional mechanisms for induction of 5-HT1A receptor mRNA and protein in activated B and T lymphocytes. J Biol Chem 276:4382-4388.
10. Kronfol Z, Remick DG 2000 Cytokines and the brain: Implications for clinical psychiatry. Am J Psychiatry 157:683-694.
11. Falaschi P, Martocchia A, Proietti A, Pastore R, D'Urso R, Barnaba V 1994 Neuroendocrinoimmunology. Ann Ital Med Int 9:96-99.
12. Lawrence DA, Kim D 2000 Central/peripheral nervous system and immune responses. Toxicology 142:189-201.
13. Reichlin S 1993 Neuroendocrine-immune interactions. N Engl J Med 329:1246-1253.
14. Blalock JE 1989 A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 69:1-32.
15. Ader R 2000 On the development of psychoneuroimmunology. Eur J Pharmacol 405:167-176.
16. Ader R, Felten D, Cohen N 1990 Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol 30:561-602.
17. Ershler WB, Harman SM, Keller ET 1997 Immunologic aspects of osteoporosis. Dev Comp Immunol 21:487-499.
18. Gruber HE 1991 Bone and the immune system. Proc Soc Exp Biol Med 197:219-225.
19. Kong YY, Boyle WJ, Penninger JM 1999 Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 77:188-193.
20. Bab IA, Einhorn TA 1993 Regulatory role of osteogenic growth polypeptides in bone formation and hemopoiesis. Crit Rev Eukaryot Gene Expr 3:31-46.
21. Kubera M, Cyrul W, Basta-Kaim A, Budziszewska B, Leskiewicz M, Holan V 2000 Effect of repeated desipramine and fluoxetine administration on post-adjuvant arthritis. Pol J Pharmacol 52:229-235.
22. Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ 1994 Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 6:267-278.
23. Mossner R, Lesch KP 1998 Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 12:249-271.
24. Barker EL, Moore KR, Rakhshan F, Blakely RD 1999 Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705-4717.
25. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S 1997 Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 6:47-56.
26. Battaglino R, Kim D, Fu J, Vaage B, Fu X-Y, Stashenko P 2002 C-myc is required for osteoclast differentiation. J Bone Miner Res 17:763-773.
27. Hansson SR, Mezey E, Hoffman BJ 1999 Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 89:243-265.
28. Shuey DL, Sadler TW, Lauder JM 1992 Serotonin as a regulator of craniofacial morphogenesis: Site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46:367-378.
29. Moiseiwitsch JR, Raymond JR, Tamir H, Lauder JM 1998 Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular explant cultures. Arch Oral Biol 43:789-800.
30. Byrd KE, Sheskin TA 2001 Effects of post-natal serotonin levels on craniofacial complex. J Dent Res 80:1730-1735.
31. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A 2000 Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275:4858-4864.
32. Emanuelsson H, Carlberg M, Lowkvist B 1988 Presence of serotonin in early chick embryos. Cell Differ 24:191-199.
33. Cornea-Hebert V, Riad M, Wu C, Singh SK, Descarries L 1999 Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187-209.
34. Doherty MD, Pickel VM 2000 Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864:176-185.
35. Fanburg BL, Lee SL 1997 A new role for an old molecule: Serotonin as a mitogen. Am J Physiol 272:L795-L806.
36. Mossner R, Lesch KP 1998 Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 12:249-271.
37. Young MR, Matthews JP 1995 Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology 84:148-152.
38. Shuey DL, Sadler TW, Lauder JM 1992 Serotonin as a regulator of craniofacial morphogenesis: Site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46:367-378.
39. Hansson SR, Mezey E, Hoffman BJ 1999 Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 89:243-265.
40. Moiseiwitsch JR, Raymond JR, Tamir H, Lauder JM 1998 Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular explant cultures. Arch Oral Biol 43:789-800.
41. Tecott L, Shtrom S, Julius D 1995 Expression of a serotonin-gated ion channel in embryonic neural and nonneural tissues. Mol Cell Neurosci 6:43-55.
42. Lauder JM, Wilkie MB, Wu C, Singh S 2000 Expression of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in the mouse embryo. Int J Dev Neurosci 18:653-662.
43. English KB, Wang ZZ, Stayner N, Stensaas LJ, Martin H, Tuckett RP 1992 Serotonin-like immunoreactivity in Merkel cells and their afferent neurons in touch domes from the hairy skin of rats. Anat Rec 232:112-120.
44. Lesclous P, Guez D, Llorens A, Saffar JL 2001 Time-course of mast cell accumulation in rat bone marrow after ovariectomy. Calcif Tissue Int 68:297-303.
45. de Gennes C, Kuntz D, de Vernejoul MC 1992 Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop 279:281-291.
46. Valentijn K, Gutow AP, Troiano N, Gundberg C, Gilligan JP, Vignery A 1997 Effects of calcitonin gene-related peptide on bone turnover in ovariectomized rats. Bone 21:269-274.
47. Winding B, Wiltink A, Foged NT 1997 Pituitary adenylyl cyclase-activating polypeptides and vasoactive intestinal peptide inhibit bone resorption by isolated rabbit osteoclasts. Exp Physiol 82:871-886.
48. Lundberg P, Lie A, Bjurholm A, Lehenkari PP, Horton MA, Lerner UH, Ransjo M 2000 Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 27:803-810.
49. Ader R, Felten D, Cohen N 1990 Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol 30:561-602.
50. Reichlin S 1993 Neuroendocrine-immune interactions. N Engl J Med 329:1246-1253.
51. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ 2001 Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968.
52. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM 2001 Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486.
53. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
54. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
55. Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F, Esler M 2004 Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 286:E744-E752.
56. Yamada J, Sugimoto Y, Hirose H, Kajiwara Y 2003 Role of serotonergic mechanisms in leptin-induced suppression of milk intake in mice. Neurosci Lett 348:195-197.
57. Greenberg BD, Li Q, Lucas FR, Hu S, Sirota LA, Benjamin J, Lesch KP, Hamer D, Murphy DL 2000 Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet 96:202-216.
58. Liu W, Gu N, Feng G, Li S, Bai S, Zhang J, Shen T, Xue H, Breen G, St Clair D, He L 1999 Tentative association of the serotonin transporter with schizophrenia and unipolar depression but not with bipolar disorder in Han Chinese. Pharmacogenetics 9:491-495.
59. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M 1998 Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
60. Coelho R, Silva C, Maia A, Prata J, Barros H 1999 Bone mineral density and depression: A community study in women. J Psychosom Res 46:29-35.
61. Halbreich U, Palter S 1996 Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes. Schizophr Bull 22:447-454.
62. Herran A, Amado JA, Garcia-Unzueta MT, Vazquez-Barquero JL, Perera L, Gonzalez-Macias J 2000 Increased bone remodeling in first-episode major depressive disorder. Psychosom Med 62:779-782.
63. Licinio J, Wong ML 1999 The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 4:317-327.
64. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, Gold P 1996 Bone mineral density in women with depression. N Engl J Med 335:1176-1181.
65. Schweiger U, Weber B, Deuschle M, Heuser I 2000 Lumbar bone mineral density in patients with major depression: Evidence of increased bone loss at follow-up. Am J Psychiatry 157:118-120.